EGFR and lung cancer: Given the successful development of tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) for the treatment of individuals with lung cancer positive for EGFR mutations (Paez et al, 2004), the identification of other kinases implicated in lung cancer would be expected to facilitate the development of new molecularly targeted therapies.